Published finding — does the expert body still believe it?
The KEYNOTE-522 trial's stated primary conclusion — Neoadjuvant pembrolizumab + chemotherapy increases pathologic complete response rate in triple-negative breast cancer. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al. · New England Journal of Medicine · 2020
· openalex W3006930853
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1545
The KEYNOTE-189 trial's stated primary conclusion — Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations. — replicates in independent cohorts.
0.1707
Recent follow-up analyses of KEYNOTE-522 are confirming the original effect size in real-world data.
0.1866
By 2028, neoadjuvant checkpoint inhibition will be standard-of-care for stage II–III TNBC across major oncology guidelines.
0.1914
Recent follow-up analyses of KEYNOTE-189 are confirming the original effect size in real-world data.
0.2145
The MONALEESA-2 trial's stated primary conclusion — Adding ribociclib to letrozole improves progression-free survival in HR+/HER2− advanced breast cancer. — replicates in independent cohorts.
0.2179
The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.